To Evaluate the Efficacy and Safety of JW0201 Added on in Patients With Type 2 Diabetes Mellitus
NCT05814393
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
200
Enrollment
INDUSTRY
Sponsor class
Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG:
Treatment Period(JW0201)
DRUG:
Treatment Period(Placebo)
DRUG:
Extension Period(JW0201)
Sponsor
JW Pharmaceutical